Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Decitabine (Primary) ; Vemurafenib (Primary) ; Cobimetinib
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms ML28604
- 17 Sep 2018 Status changed from active, no longer recruiting to discontinued due to loss of funding.
- 25 Jun 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 25 Jun 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.